AbbVie (ABBV) Granted HUMIRA (adalimumab) Patent License with Mylan (MYL)
Tweet Send to a Friend
AbbVie (NYSE: ABBV) announced today patent license agreements with Mylan (NASDAQ: MYL) over its proposed biosimilar adalimumab product. Under ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
